BioMarin Pharmaceutical Q3 Non-GAAP Earnings, Revenue Rise; 2026 Guidance Lowered

04:25 PM EST, 11/02/2026 (MT Newswires) -- BioMarin Pharmaceutical (BMRN) reported Q3 non-GAAP earnings late Monday of $0.23 per diluted share, up from $0.12 a year earlier. Analysts polled by FactSet expected a loss of $0.09. Revenue for the quarter ended Sept. 30 rose to $1.02 billion from $776.1 million a year earlier. Analysts expected $1.02 billion. The company now expects 2026 non-GAAP EPS of $2.80 to $3.10 on revenue of $3.80 billion to $3.90 billion, down from its prior guidance of non-GAAP EPS of $4.90 to $5.10 on revenue of $3.875 billion to $3.925 billion. Analysts expect $3.53 and $3.92 billion, respectively. Shares of BioMarin fell 4.2% in after-hours trading.